Latest News and Press Releases

ABRAZO Phase 2 Study Meets Protocol-Specified Criteria to Expand Enrollment EMBRACA Phase 3 Study Enrollment Completion Targeted 1H 2016 SAN RAFAEL, Calif., July 20, 2015 (GLOBE NEWSWIRE) --...

SAN RAFAEL, Calif., July 15, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin, will host a...

FDA Grants Priority Review Status FDA PDUFA Date is December 27, 2015 SAN RAFAEL, Calif., June 29, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the U.S....

SAN RAFAEL, Calif., June 25, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the European Medicines Agency (EMA) has validated the Marketing Authorization...

- 50% Increase in mean annualized growth velocity in 15 µg/kg/daily dose group - BMN 111 was well tolerated across all three dose cohorts - Phase 2 findings support program advancement of...

SAN RAFAEL, Calif., June 15, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that EY awarded BioMarin CEO Jean-Jacques Bienaimé the EY Entrepreneur Of The...

SAN RAFAEL, Calif., June 8, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the submission of a Marketing Authorization Application (MAA) to the European Medicines...

SAN RAFAEL, Calif., June 4, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer at BioMarin, will present a...

SAN RAFAEL, Calif., May 1, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer at BioMarin,...

- Vimizim Sales Top $50 million in First Quarter of 2015 and $127 million in First Four Quarters Since Launch - Full-year Vimizim Guidance Increased to $200 million to $220 million; Full-year...